AB0657 Genetic and Clinical Predictors of Response to Tnf-Alpha Therapy in an Italian Axial-Spa Cohort
Autor: | S. Canestri, Barbara Tolusso, M.C. Miceli, L. Messuti, G. F. Ferraccioli, M. Nowik, D. Simone, R. Privitera, Elisa Gremese, C. Di Mario |
---|---|
Rok vydání: | 2014 |
Předmět: |
medicine.medical_specialty
Ankylosing spondylitis business.industry Immunology Disease medicine.disease General Biochemistry Genetics and Molecular Biology Rheumatology Polymorphism (computer science) Rheumatoid arthritis Internal medicine Cohort Genotype medicine Immunology and Allergy business BASDAI Body mass index |
Zdroj: | Annals of the Rheumatic Diseases. 73:1022.2-1022 |
ISSN: | 1468-2060 0003-4967 |
DOI: | 10.1136/annrheumdis-2014-eular.4272 |
Popis: | Background The genetic background has been demonstrated to be important in the pathogenesis of spondyloarthritides. Several genes besides HLA-B27 have shown to be correlated to the development of several clinical manifestations within the spectrum of spondyloarthritides. It is known that other factors (gender, body mass index) can influence the response to treatments in spondyloarthritis. Objectives We aimed to evaluate the frequency of the polymorphism of the enhancer HS1,2A of the Ig Heavy 39 regulatory region, previously described as associated to autoimmune conditions (rheumatoid arthritis, systemic sclerosis, systemic lupus erythematosus), in patients with spondyloarthritis (SpA), and to identify a correlation of this genetic factor to a specific phenotype of the disease or to a different response to therapy. We also aimed to identify other predictors of response to the anti-TNFa treatment among genetic and clinical factors. Methods We evaluated 153 patients with a diagnosis of axial-SpA according to the 2009 ASAS criteria, of which 125 had differentiated forms (ankylosing spondylitis, psoriatic spondyloarthritis or IBD-associated spondyloarthritis; 77 men, average age 39.6±7.9 years, 77.6% in treatment with anti-TNFa agents and 22.4% at the second treatment) and 28 undifferentiated spondyloarthritis (uSpA) (12 men, average age 42.5±15.7 years, 78.6% treated with anti-TNFa agents) to identify predictors for disease-activity outcome at the last follow up available. BASDAI and ASDAS were used to assess the clinical response. Selective polymerase chain reaction of the region containing polymorphic HS1,2A alleles was performed on all patients after informed consent [1]. Results The frequency of 2/2 genotype of the HS1,2A enhancer was significantly increased in patients with spondyloarthritis compared to healthy controls (40.9% vs 15.7%, p 25 and not-carriers of the 2/2 genotype of HS1,2A showed to be slower responder to the anti-TNFa. Conclusions Our data show an association in spondyloarthritis with the allele 2 of the gene enhancer HS1,2A, similarly for what already observed in other autoimmune diseases (rheumatoid arthritis, systemic sclerosis, systemic lupus erythematosus). We also show that BMI, sex [2] and the presence of a specific polymorphism of gene HS1,2A might influence the response to the anti-TNFa therapy. References Tolusso B et al., Ann Rheum Dis 2009. Gremese E et al. J Rheumatol 2014. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.4272 |
Databáze: | OpenAIRE |
Externí odkaz: |